170 related articles for article (PubMed ID: 6411830)
1. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.
Pier GB; Thomas DM
J Infect Dis; 1983 Aug; 148(2):206-13. PubMed ID: 6411830
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Sadoff JC; Ohman D; Fürer E
J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
Pier GB
J Clin Invest; 1982 Feb; 69(2):303-8. PubMed ID: 6799548
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.
Pier GB; Bennett SE
J Clin Invest; 1986 Feb; 77(2):491-5. PubMed ID: 3080477
[TBL] [Abstract][Full Text] [Related]
5. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
[TBL] [Abstract][Full Text] [Related]
6. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.
Tarkowski A; Lue C; Moldoveanu Z; Kiyono H; McGhee JR; Mestecky J
J Immunol; 1990 May; 144(10):3770-8. PubMed ID: 2110213
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.
Kronborg G; Fomsgaard A; Galanos C; Freudenberg MA; Høiby N
J Clin Microbiol; 1992 Jul; 30(7):1848-55. PubMed ID: 1378455
[TBL] [Abstract][Full Text] [Related]
8. The clinical relevance of IgM and IgA anti-pneumococcal polysaccharide ELISA assays in patients with suspected antibody deficiency.
Janssen LMA; Heron M; Murk JL; Leenders ACAP; Rijkers GT; de Vries E
Clin Exp Immunol; 2021 Aug; 205(2):213-221. PubMed ID: 33877708
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.
Pier GB; Thomas D; Small G; Siadak A; Zweerink H
Infect Immun; 1989 Jan; 57(1):174-9. PubMed ID: 2491835
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
[TBL] [Abstract][Full Text] [Related]
11. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of human IgG, IgM, and IgA antibody directed to the capsule of Haemophilus influenzae type b.
Schreiber JR; Barrus V; Cates KL; Siber GR
J Infect Dis; 1986 Jan; 153(1):8-16. PubMed ID: 3484506
[TBL] [Abstract][Full Text] [Related]
13. Experimental immunization with Pseudomonas aeruginosa alginate induces IgA and IgG antibody responses.
Johansen HK; Høiby N; Pedersen SS
APMIS; 1991 Dec; 99(12):1061-8. PubMed ID: 1772641
[TBL] [Abstract][Full Text] [Related]
14. Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin.
Garbett ND; Munro CS; Cole PJ
Clin Exp Immunol; 1989 Apr; 76(1):8-12. PubMed ID: 2500275
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Furer E; Sadoff JC; Germanier R
Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
[TBL] [Abstract][Full Text] [Related]
16. Immunologic basis for mouse protection provided by high-molecular-weight polysaccharide from immunotype 1 Pseudomonas aeruginosa.
Markham RB; Pier GB
Rev Infect Dis; 1983; 5 Suppl 5():S957-62. PubMed ID: 6419317
[TBL] [Abstract][Full Text] [Related]
17. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis.
Skevakis L; Frasch CE; Zahradnik JM; Dolin R
J Infect Dis; 1984 Mar; 149(3):387-96. PubMed ID: 6425422
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
Cripps AW; Peek K; Dunkley M; Vento K; Marjason JK; McIntyre ME; Sizer P; Croft D; Sedlak-Weinstein L
Infect Immun; 2006 Feb; 74(2):968-74. PubMed ID: 16428742
[TBL] [Abstract][Full Text] [Related]
19. Factors in human serum promoting phagocytosis of Pseudomonas aeruginosa. I. Interaction of opsonins with the bacterium.
Bjornson AB; Michael JG
J Infect Dis; 1974 Nov; 130 Suppl(0):S119-26. PubMed ID: 4214223
[No Abstract] [Full Text] [Related]
20. Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides.
Lang AB; Fürer E; Schürch U; Cross AS; Larrick JW; Cryz SJ
Dev Biol Stand; 1990; 71():121-6. PubMed ID: 1698165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
